ICU MEDICAL INC (ICUI)
Health Care · Medical Devices / Infusion Therapy · NASDAQ
A medical device manufacturer specializing in comprehensive infusion therapy systems and critical care technology.
What ICU MEDICAL INC does
ICU Medical develops, manufactures, and sells medical devices and systems for infusion therapy, oncology, and critical care. The company's portfolio includes syringe and ambulatory infusion pumps, as well as various infusion consumables, designed to support clinical workflows in hospital and healthcare environments.
Themes: infusion therapy, critical care medical devices, hospital medical equipment
Fundamentals
- Price$157.18 as of 2026-10-08 close
- Market cap$3.9B as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+30.6% 2025-10-08 close $120.31 → 2026-10-08 close $157.18
- P/E84.87 as of 2026-10-08
- Net margin+0.0% FY2025, SEC XBRL
- Gross margin+36.8% FY2025, SEC XBRL
- ROE+0.0% FY2025, SEC XBRL
- Debt / equity0.61 as of 2026-09-03
- Revenue growth (YoY)-10.9% as of 2026-09-03
- Revenue CAGR (3y)-0.7% SEC XBRL
- Beta1.01 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How ICUI compares in its sector
- price-to-earnings ratiotop 25% 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginbottom 25% 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ICUI is not currently in any published Top 10 list. Its scores are below.
Top 10 score
32.5 #1327 of 1,379 scored · #144 of 151 in Health Care
Trend 61st (over the past 12 months this stock beat the market by 15.7 percentage points) and valuation 44th (price to book 1.8, price to earnings 84.9); weakest is growth (11th, revenue growth year over year -10.9%, 3-year revenue CAGR -0.7%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How ICU MEDICAL INC looks technically
ICU MEDICAL INC (ICUI) is trading 6.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 61 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 15 trading days ago. It is 18.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 6.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +6.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $168.59 | $168.59 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $147.33 | $147.33 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 167.67. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 61 trading days ago — a "golden cross", a bullish long-term signal | 61 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 15.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 41.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($152.49 to $167.67) — its "stochastic" reading is 31 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 30.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $192.85 | $192.85 |
|---|---|---|
| From the 52-week high | it is 18.5% below its 52-week high (its highest price of the past year) | -18.5% |
| Above the 52-week low | it is 39.7% above its 52-week low (its lowest price of the past year) | +39.7% |
| Below the 52-week high | it is 18.5% below its highest point of the past year | 18.5% |
| Since a 20-day breakout | it made a new 20-day low about 15 trading days ago | 15 sessions |
| Since a 55-day breakout | it made a new 55-day high about 36 trading days ago | 36 sessions |
| All-time high | its highest closing price on record is $321.70 (set on 2018-08-10) | $321.70 |
| Given back of the 52-week move | over the past year its closes ranged ($114.13 to $187.26), and it has given back roughly a third of its rise from last year’s low — 41% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $139.73 to $142.07. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 41.1% |
| From the all-time high | it is 51.1% below its all-time high | -51.1% |
| Nearest price level | it is trading 1.5% above a support level at $154.81 — a price it turned at five times since 2024-12-05, most recently on 2026-02-10. Since 2024-10-08 it has 13 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.5% |
| All-time low | its lowest closing price on record is $22.14 (set on 2008-06-19) | $22.14 |
| Above the all-time low | it is 609.9% above its all-time low | +609.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) | 14th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $4.65 between its high and its low — about 3.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $4.65 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $151.31 and $166.74 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $151.31 – $159.03 – $166.74 |
| Typical daily range (% of price) | its price moves about 3.0% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.0% |
| Stretch from the 200-day average | it is trading 2.1 daily ranges above its 200-day average price (6.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.88× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Gap filled | a 9.6% gap up opened on 2026-08-07 has been "filled" 24 sessions ago — price traded back through the level the gap left behind, and it took 19 sessions to close | 24 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 3.3 percentage points (the stock lost 2.3% while the market gained 1.0%) | -3.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 0.3 percentage points (the stock gained 3.5% while the market gained 3.8%) | -0.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 10.3 percentage points (the stock gained 27.8% while the market gained 17.5%) | +10.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 15.7 percentage points (the stock gained 30.6% while the market gained 15.0%) | +15.7% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 4.1% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 9.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -4.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $147.85 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +6.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $169.34 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -7.2% |
Head and shoulders, bearish — forming · entry $152.37 · 59 sessions in
Price levels it has turned at before
ICUI last closed at $157.18 on 2026-10-08. Since 2024-10-08 it has turned at 13 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $154.81 | Support | 1.5% below the last close | turned there five times · 2024-12-05 to 2026-02-10 |
| $161.46 | Resistance | 2.7% above the last close | turned there five times · 2024-11-14 to 2026-07-17 |
| $151.21 | Support | 3.8% below the last close | turned there 10 times · 2024-12-19 to 2026-09-18 |
| $164.63 | Resistance | 4.7% above the last close | turned there twice · 2025-02-19 to 2026-08-06 |
| $146.14 | Support | 7.0% below the last close | turned there three times · 2026-01-14 to 2026-06-16 |
| $168.38 | Resistance | 7.1% above the last close | turned there four times · 2024-11-01 to 2026-09-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $167.67.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $100.49 and $126.15 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $167.67.
This reading has stood for 6 trading days, since 2026-10-01.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · trendless / choppy (low ADX) · beating the market · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud · Elliott wave 3 candidates | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$193.38 range $178.00 – $210.00; median $192.50
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ICUI
- Consensus EPS estimate$2.15 next reporting period, as of 2026-10-09
- Estimate change, 30 days$0.00 (0.0%) from $2.15, on 2026-09-04, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Regulatory and compliance risks related to FDA warning letters impacting product commercialization.","Operational and financial risks associated with the integration of acquired businesses, particularly Smiths Medical.","Supply chain dependencies on single or limited-source third-party suppliers."]
What changed in the latest 10-Q
AI-assisted comparison of ICUI's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- In newer filing (2026-05-07): Added reference to 'our 2025 Annual Report on Form 10-K' instead of 2024 Form 10-K
- In newer filing (2026-05-07): Added 'We also offer IV Solutions products through a commercial relationship with the joint venture' in Business Overview section
- In newer filing (2026-05-07): Changed product portfolio description from 'peripheral IV catheters, and sterile IV solutions' to 'peripheral IV catheters' with separate statement about IV Solutions through joint venture
- Removed:
- In older filing (2025-11-06): Reference to 'our 2024 Annual Report on Form 10-K' removed in newer version
- In older filing (2025-11-06): Direct mention of 'sterile IV solutions' as part of product portfolio removed in newer version
- In older filing (2025-11-06): Marketing language in Plum Duo/Solo description ('which recently received FDA 510(k) clearance during April 2025, are a new category of precision pumps that bring unprecedented accuracy and unmatched usability') removed in newer version
- Reworded:
- Plum Duo/Solo description: Newer (2026-05-07) uses more clinical/technical language ('are single-channel and dual-channel infusion pump systems that received FDA 510(k) clearance in April 2025') versus older (2025-11-06) marketing-focused language ('which recently received FDA 510(k) clearance during April 2025, are a new category of precision pumps that bring unprecedented accuracy')
- Plum Duo/Solo description: Newer version reorganized to separate technical specifications from feature descriptions; older version integrated marketing claims with technical specs
- Table of Contents page numbers: Changed from page 40 and 41 in older filing to page 36 and 37 in newer filing
- Notes:
- The Plum 360 KLAS awards section is truncated in both texts, making full comparison of that portion impossible
- Both filings appear to be quarterly reports (10-Q) for different fiscal periods, which naturally account for some reference date changes
Risk Factors
- Added:
- Newer filing (2026-05-07) adds reference to 'the Middle East' in geopolitical conflicts listing, changing from 'armed conflicts between Ukraine and Russia and in Israel' to 'armed conflicts between Ukraine and Russia and in the Middle East'
- Newer filing (2026-05-07) removes 'our expected use of proceeds from the New Credit Facilities (as defined below)' from forward-looking statements list
- Newer filing (2026-05-07) reorganizes FDA warning letter risk to appear as a separate bullet point rather than combined with other compliance risks
- Newer filing (2026-05-07) removes 'and' at end of Smiths Medical acquisition bullet point, making it the second-to-last item
- Removed:
- Older filing (2025-11-06) language 'will escalate trade wars and will have a material adverse effect on our results of operations' removed from tariff/trade policy bullet point in newer filing (2026-05-07)
- Older filing (2025-11-06) reference to 'global health concerns' removed from FDA disruptions bullet point in newer filing (2026-05-07), replaced with 'policy changes'
- Older filing (2025-11-06) language 'could affect the safety or effectiveness of these devices and' removed from FDA warning letter risk in newer filing (2026-05-07)
- Older filing (2025-11-06) includes 'and' at end of Smiths Medical acquisition risk bullet point; newer filing (2026-05-07) removes this conjunction
- Reworded:
- Reference to '2024 Annual Report on Form 10-K for the fiscal year ended December 31, 2024' in older filing (2025-11-06) changed to '2025 Annual Report on Form 10-K for the fiscal year ended December 31, 2025' in newer filing (2026-05-07)
- Geopolitical reference changed from 'Israel' (older filing 2025-11-06) to 'the Middle East' (newer filing 2026-05-07)
- FDA risk bullet language simplified: older filing (2025-11-06) states risks 'could affect the safety or effectiveness of these devices and could impact our continued commercial activity'; newer filing (2026-05-07) states risks 'could impact our continued commercial activity'
- Notes:
- Comparison limited to Forward-Looking Statements section and table of contents of Risk Factors portion; full Risk Factors content not provided in either filing text
- Financial statement dates differ between filings (March 31, 2026 vs. September 30, 2025 / December 31, 2025 vs. December 31, 2024), reflecting different quarter-end reporting periods
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 13 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 13 sells ($7M) — 6 selling insiders
- Last 180 days · read to 2026-10-040 buys · 16 sells ($8M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-03. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ICUI's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for ICUI from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
4 institutional 13F filers reported holding ICUI as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 6,193,823
- Reported value $908,019,169
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ICUI's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ICUI had 1,515,688 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ICUI had 6.06% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.29 days to cover at the same settlement.
- Reported short interest (shares) 1,515,688
- Short interest (% of shares outstanding) 6.06%
- Prior settlement (shares) 1,433,092
- Reported change 5.76%
- Days to cover (reported) 6.29
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Baxter International (BAX)
- Becton, Dickinson and Company (BDX)
- B. Braun Melsungen AG
- Fresenius Kabi
- Moog Inc. (MOG.A)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ICUI vs…
Frequently asked questions
What does ICU MEDICAL INC (ICUI) do?
ICU Medical develops, manufactures, and sells medical devices and systems for infusion therapy, oncology, and critical care. The company's portfolio includes syringe and ambulatory infusion pumps, as well as various infusion consumables, designed to support clinical workflows in hospital and healthcare environments.
What sector is ICU MEDICAL INC (ICUI) in?
ICU MEDICAL INC (ICUI) is classified in the Health Care sector. Its industry is Medical Devices / Infusion Therapy. It trades on NASDAQ.
Who are ICU MEDICAL INC's (ICUI) competitors?
Notable peers of ICU MEDICAL INC (ICUI) include Baxter International, Becton, Dickinson and Company, B. Braun Melsungen AG, Fresenius Kabi and Moog Inc.. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in ICUI?
Yes — we hold 1 matched STOCK Act disclosure for ICUI from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is ICU MEDICAL INC (ICUI) overbought or oversold right now?
ICU MEDICAL INC (ICUI) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ICUI come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.